RGC - MCAP CO - Regencell Bioscience

The breakdown in relations between Washington and Beijing is blocking the exchange of biodata, which is hindering the development of new neurological drugs. Regencell Bioscience (RGC) is minimizing R&D risks by studying Eastern medicine methods for the therapy of autism and ADHD. To reduce the cost of compound screening, the company is implementing AI algorithms. Current market capitalization stands at 3.02. The price action is presented below and clearly demonstrates the issuer's market position.

Market capitalization is determined by the product of the current share price and the total number of outstanding securities, reflecting the objective market value of the entire business. This indicator allows for an assessment of the asset's resilience to sell-offs, which is critical for Regencell Bioscience (RGC) amid the high risk of clinical trial failure and resource depletion, clearly illustrating these processes through the company's exchange-traded capitalization.